Semaglutide 2.4 mg (Wegovy) typically produces ~15% weight reduction, liraglutide 3.0 mg (Saxenda) ~8%, and tirzepatide (Zepbound) ~15-21%
Look for cuts, bruises, redness, or irritation
Additional mistakes to avoid: Injecting through clothing rather than directly into clean, exposed skin Failing to rotate injection sites adequately, leading to lipohypertrophy Injecting cold medication directly from the refrigerator (if product IFU recommends warming) Removing the needle too quickly before the full dose is delivered Rubbing the injection site vigorously after injection Disposing of needles in regular trash rather than FDA-approved sharps containers Improper storage of medications is another significant concern
Glucagon-like peptide-1 (GLP-1) is a hormone produced by the small intestine, which is responsible for triggering the pancreas to release insulin, blocking the secretion of another hormone called glucagon, slowing digestion, and making you feel full after eating
Key takeaways GLP-1 medications treat type 2 diabetes and obesity by mimicking a hormone that helps manage blood sugar
